Ad-Mist™, new airless spray nozzle to deliver a mist of fine droplets, including viscous formulations

EVEON has developed Ad-Mist™, an airless spray nozzle that can be used to produce fine droplets in the form of a mist. This spray nozzle can be integrated into dedicated automatic medical devices to facilitate the administration of treatments by the patient, or simply connected directly to a syringe.

EVEON has designed and patented Ad-Mist™, a spray nozzle, requiring neither air nor a propellant, which adapts to formulations of every viscosity, including highly viscous formulations (up to 8.000 Pa·s depending on the rheological properties of the product). This innovation can be used to deliver a mist of fine droplets of about 20 microns in diameter in a perfectly repeatable manner, thereby favouring absorption by mucous membranes and limiting the dose of product to be delivered.

Moreover, this fine mist generates low impact pressure on the surface to be treated, which makes it suitable for therapeutic applications when the mucous membranes are particularly sensitive. One of the key design elements from the beginning has been the airless, propellant-free feature, so as to aerosolise the drug without oxidising it and to propose a more ecological alternative to existing products.

Ad-Mist™ can be connected to a syringe via a Luer, for continuous, manual administration of the spray. If precise control of administration is required, this spray nozzle can be integrated into the Intuity® Spray automatic medical device. Thanks to its unique electronic and fluidic characteristics, this easy-to-use, tailored medical device offers controlled flowrate and dosage for precise administration of doses from 15µL to several mL. It can also be used to automatically reconstitute lyophilised biological drugs.

With its unique performance, the airless spray nozzle Ad-Mist™ offers optimal results and responds to an increasing demand for non-invasive spray or mist administration of drugs, including viscous drugs, thereby improving patient acceptance,” said Vincent TEMPELAERE, CEO of EVEON.

Administering drugs in the form of a spray, particularly topical administration on the skin or mucous membranes, is a major trend. Sustained market growth is expected, with an annual rate of +7.3% between now and 2026, for mucosal administrations. Compared to parenteral routes, sprays offer undeniable advantages. As an easy-to-use, non-invasive medical device, they can improve therapeutic adherence, particularly for self-administration. At the same time, the medical products market is constantly evolving, with a rise in highly viscous formulations.